A Southern District of New York judge has sanctioned a plaintiffs lawyer and reduced the jury award in one of the bellwether cases in the multidistrict litigation over the anti-osteoporosis drug Fosamax.
Judge John F. Keenan on Monday said the $8 million verdict returned by a jury in June in favor of plaintiff Shirley Boles was “excessive” and gave Boles the option of either getting a retrial on damages or taking $1.5 million. The first trial ended in a mistrial last year when the jury, who could be heard by the lawyers arguing loudly in the jury room, deadlocked 7-1.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Not a Bloomberg Law Subscriber?
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]